Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on February 21, 2014. The report details a material definitive agreement regarding a private placement offering and changes to the Board of Directors.
Key Financial Metrics and Capital Structure
- Capital Raised: Agreements entered for the sale of $1.35 million in Units.
- Unit Composition: Each Unit priced at $3.00, consisting of one share of common stock, one Series A warrant, and a pro-rata portion of Series B warrants.
- Transaction Costs: Placement agent commission paid to Dawson James Securities, Inc. totaled $94,630.
- Use of Proceeds: Anticipated for working capital and general corporate purposes.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or debt metrics; it is a current report on specific events.
Material Changes and Corporate Actions
Private Placement Offering
- Series A Warrants: Exercisable at $3.00 per share; expire five years from issuance.
- Series B Warrants: Total allotment of 1,400,000 shares. Exercise price is $3.63 per share. Not exercisable for six months post-closing.
- Contingency: Series B Warrants vest only upon the closing of the initial public offering (IPO) of the subsidiary, Ruthigen, Inc. If the IPO does not close by March 31, 2014, the Series B Warrants terminate.
- Placement Agent Warrant: Dawson James Securities received a warrant to purchase up to 69,037 shares at $3.00 per share, expiring May 3, 2016.
Board of Directors Changes
- Appointment: Russell Harrison appointed as Director on February 26, 2014. He chairs the Nominating and Corporate Governance Committee and serves on the Audit and Compensation Committees.
- Compensation: Annual retainer of $25,000 plus committee fees totaling $12,000. Granted an initial option to purchase 7,143 shares vesting over three years.
- Departure: Gregory French resigned as a Director on February 21, 2014.
Guidance, Risks, and Contingencies
- Offering Closing: Expected to close on or about February 26, 2014, subject to customary conditions.
- Registration Status: Shares and Series A Warrants are registered under a shelf statement. Series B Warrants are unregistered and sold under an exemption for qualified institutional buyers.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties, noting that actual results may differ from expectations.
Investor Verification Checklist
- Verify the closing date of the $1.35 million offering (expected Feb 26, 2014).
- Monitor the status of the Ruthigen, Inc. IPO; failure to close by March 31, 2014, will void the Series B Warrants.
- Review the impact of the new director's stock option grant on future dilution.
- Confirm the final number of Series B Warrants issued, as they were rounded based on individual investor percentages.